Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.
Covered in this story
Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.